Pancreatic Adenocarcinoma Treatment Global Market Report 2025

The pancreatic adenocarcinoma treatment market size has grown rapidly in recent years. It will grow from $2.13 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth during the historic period can be attributed to the rising incidence of pancreatic cancer, advancements in chemotherapy and radiation therapy, increased awareness and early diagnosis, regulatory approvals of new treatments, and growing investment in oncology research.

The pancreatic adenocarcinoma treatment market size is expected to see rapid growth in the next few years. It will grow to $3.99 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth during the forecast period can be driven by the expansion of targeted and immunotherapy treatments, increasing adoption of precision medicine, advancements in biomarker-based diagnostics, rising healthcare expenditure, and a growing number of clinical trials for novel therapies. Major trends include the development of AI-driven drug discovery, expansion of nanomedicine for targeted drug delivery, adoption of liquid biopsy for early detection, advancements in CRISPR-based gene therapy, and the integration of telemedicine for treatment monitoring.

The rising prevalence of digestive system cancers is expected to drive the growth of the pancreatic adenocarcinoma treatment market. These cancers develop in organs involved in digestion, including the stomach, liver, pancreas, intestines, esophagus, and colon. The increasing incidence of such malignancies is largely attributed to unhealthy lifestyle choices such as poor diet, alcohol consumption, and smoking. Pancreatic adenocarcinoma treatment plays a vital role in managing one of the most aggressive cancers of the digestive system, with the goal of improving survival rates and enhancing patients' quality of life. For example, in January 2023, the American Cancer Society, a US-based non-profit organization, estimated that 64,050 individuals in the United States would be diagnosed with pancreatic cancer, while 50,550 were expected to succumb to the disease. As a result, the growing incidence of digestive system cancers is contributing to the expansion of the pancreatic adenocarcinoma treatment market.

Leading companies in the pancreatic adenocarcinoma treatment market are prioritizing the development of innovative therapies, such as irinotecan liposome injection, to enhance treatment efficacy, minimize side effects, and address tumor resistance challenges. Irinotecan liposome injection is a chemotherapy drug encapsulated in liposomes, designed to improve drug delivery to cancer cells, increase effectiveness, and reduce adverse effects in the treatment of pancreatic adenocarcinoma. For instance, in February 2024, Ipsen SA, a France-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental new drug application for Onivyde (irinotecan liposome injection) in combination with oxaliplatin. This combination enhances tumor targeting by improving drug delivery while minimizing side effects compared to conventional therapies. The liposomal formulation increases the bioavailability and sustained release of irinotecan, while oxaliplatin provides additional efficacy against pancreatic cancer cells. The approval highlights the regimen’s potential to fulfill the need for more effective treatment options for this aggressive cancer.

In February 2022, Panbela Therapeutics Inc., a US-based biopharmaceutical company, acquired Cancer Prevention Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows Panbela to expand its oncology pipeline by incorporating the clinical-stage assets of both companies, including SBP-101, which has shown promise in improving overall survival and response rates in metastatic pancreatic adenocarcinoma patients. This development aims to enhance treatment options for this highly aggressive cancer. Cancer Prevention Pharmaceuticals Inc. is a US-based biotechnology company specializing in innovative therapeutics designed to lower cancer risk and recurrence, with a particular focus on familial adenomatous polyposis (FAP), colorectal cancer prevention, and other rare diseases.

Major players in the pancreatic adenocarcinoma treatment market are Pfizer Inc., Roche AG, Merck & Co Inc., Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited (Japan), Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd, Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen SA, Clovis Oncology Inc., Oncolytics Biotech Inc., Zydus Cadila, PharmaCyte Biotech Inc., and Infinity Pharmaceuticals Inc.

North America was the largest region in the pancreatic adenocarcinoma treatment market in 2024. The regions covered in pancreatic adenocarcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pancreatic adenocarcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pancreatic adenocarcinoma treatment encompasses various medical strategies aimed at managing and combating pancreatic adenocarcinoma, the most common form of pancreatic cancer. Treatment approaches depend on factors such as cancer stage, tumor location, and patient health, typically involving a combination of surgery, chemotherapy, radiation therapy, and targeted therapies to enhance survival and quality of life.

The primary types of pancreatic adenocarcinoma treatment include chemotherapy, targeted therapy, and other modalities. Chemotherapy utilizes drugs to destroy or inhibit the growth of cancer cells and may be employed to shrink tumors before surgery, prevent recurrence post-surgery, or manage advanced stages by alleviating symptoms. The disease primarily affects the exocrine and endocrine regions of the pancreas. Treatment distribution occurs through various channels, including hospital pharmacies, retail pharmacies, and other healthcare providers.

The pancreatic adenocarcinoma treatment market research report is one of a series of new reports that provides pancreatic adenocarcinoma treatment market statistics, including pancreatic adenocarcinoma treatment industry global market size, regional shares, competitors with a pancreatic adenocarcinoma treatment market share, detailed pancreatic adenocarcinoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic adenocarcinoma treatment industry. This pancreatic adenocarcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic adenocarcinoma treatment market includes revenues earned by entities by providing services such as chemotherapy administration, radiation therapy, surgical procedures, targeted therapy, immunotherapy, supportive care services, and diagnostic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic adenocarcinoma treatment market also includes sales of chemotherapeutic drugs, targeted therapy drugs, immunotherapy agents, radiation therapy equipment, surgical instruments, diagnostic tools, and supportive care medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.